-

Brenus Pharma Joins the Paris Saclay Cancer Cluster (PSCC) to Collaborate at the Heart of Innovation in Oncology

LYON, France--(BUSINESS WIRE)--Brenus Pharma has successfully joined the Paris Saclay Cancer Cluster (PSCC), the first national Onco-cluster. This membership positions Brenus at the heart of the European initiative to accelerate and valorize innovation in oncology.

As the inaugural beneficiary of the France 2030 NextGenerationEU program, PSCC represents a paradigm shift in the pace and anticipation of oncological advancements. Dedicated to improving the predictability and efficiency of cancer research, PSCC fosters collaboration within scientific, medical, and industrial communities, providing privileged access to cutting-edge resources.

Located in Grand Paris, PSCC brings together a diverse community of 80 members from 9 different nationalities. Chaired by Professors Éric Vivier and Solange Peters, PSCC aims to promote French research and the transfer of innovations to the European and global levels in the field of oncology.

Focused on transforming the treatment of solid tumor cancers, Brenus Pharma stands out with its patented platform of anticancer vaccine immunotherapies. By joining PSCC, Brenus Pharma will have access to technological and biological platforms, expertise, and collaborative resources to accelerate its advancements while contributing to the collective ambition of the ecosystem.

For more information: www.brenus-pharma.com;https://www.parissaclaycancercluster.org/

Contacts

BRENUS
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72

Industry:

Brenus Pharma

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)
Hashtags
#Biotech
#Clinical
#Healthcare
#Immunotherapy
#PSCC

Contacts

BRENUS
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72

Social Media Profiles
Follow Brenus Pharma
More News From Brenus Pharma

AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer

LYON, France--(BUSINESS WIRE)--Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting re...

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026

LYON, France--(BUSINESS WIRE)--Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for...

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

LYON, France--(BUSINESS WIRE)--Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during do...
Back to Newsroom